Nowadays, more and more patients presented to dermatologists complaining about "red face" accompanying with burning, stinging, itchy symptoms, or not. The red face is a straightforward clinical finding of facial erythema, and it is obvious even to the untrained eyes. 1 Interval flush or persistent facial erythema could be associated with multiple diseases, such as rosacea, contact dermatitis, acne, corticosteroid-dependent dermatitis, and systemic lupus erythematosus. 1 Hence, it is an important indicator in cosmetic science analysis and dermatologic diagnostics. In the past, methods of evaluating the facial erythema, such as IGA (Investigator Global Assessment) and PSA (Patient Self-Assessment), largely depended on the observers' personal experience and were prone to significant inter-observer variability, which could produce bias with subjective clinical scoring. 2 Therefore, more precise and objective methods and techniques of erythema assessment are demanded for the aim of evaluating and quantifying the erythema. With the rapid development of spectral imaging, image processing, and optical instruments, there have been developed varieties of skin color analysis methods or instruments, such as dermatoscopy, 3,4

Ultraviolet radiation causes a variety of skin damages. Ultraviolet A exposure is associated with photoaging which is characterized by wrinkle formation and pigmentation. Ultraviolet B radiation is related to sunburn. In addition, it is a chief risk factor to develop skin cancers with chronic exposure to both types of radiation. 1 Ultraviolet protection is crucial for preventing those harmful effects, and various photoprotection methods are available, including wearing masks, sunglasses, wide-brim hats, long-sleeve clothing, and applying sunscreen. 2 Among the above-mentioned methods, sunscreen is an effective, unrestrictive, and convenient method. Face washing is an important process to keep skin sanitary and physiologic function and to remove unwanted substances, such as

Only a few of studies have reported whether Tranexamic acid (TXA) has the same benefits during total ankle replacement as hip and knee replacements. In our study, we hypothesized that TXA was effective in reducing the perioperative blood loss without increasing the risk of symptomatic venous thromboembolism of patients during total ankle replacement. We retrospectively reviewed 71 patients who underwent total ankle replacement at the foot and ankle surgery center of our institution between January 2017 and May 2021. Patients were divided into two groups according to whether they received intravenous tranexamic acid or not. Patients who received intravenous TXA showed significantly lower estimated intraoperative blood loss, hidden blood loss and total blood loss. The early AOFAS score and ROM at the first month follow up of TXA group were better than the NO-TXA group and the incidence of early wound infection and poor healing (< 1 month postoperative) was significant lower than NO-TXA group. Use of TXA was not associated with significant changes in the incidence of postoperative symptomatic venous thromboembolism. We conclude that intravenous TXA can safely and effectively reduce perioperative blood loss and the incidence of early wound infection and poor healing in total ankle replacement, without increasing the risk of symptomatic venous thromboembolism.The application of TXA following total ankle replacement helped improve ankle function and patient quality of life during the early stage.

Pacemaker implantation is becoming increasingly common in patients with breast cancer. Comprehensive treatment options, such as surgery, chemotherapy, radiation therapy, targeted therapy and immunotherapy, have greatly improved the prognosis of patients with breast cancer. In particular, radiotherapy is an important means of comprehensive breast cancer treatment that can reduce recurrence and prolong survival in high-risk patients who underwent mastectomy. The pacemaker electrical pulse generator is typically implanted subcutaneously in the left subclavian area above the pectoral muscle through the subclavian vein. The present report implemented a new method of 'temporary pacemaker electrode and permanent artificial pacemaker placement' through the right axillary vein in a patient with breast cancer. An electrical pulse generator was placed in the right subcutaneous subclavian tissue. The pacemaker was placed under the right clavicle, and the pacemaker was included as organ at risk (OAR). Dose of planning organ at risk volume (PRV) with additional 6 mm margin to the pacemaker was limited during radiotherapy planning design. This patient with breast cancer, who was also complicated with other underlying comorbidities (such as atrial fibrillation, coronary atherosclerosis, cardiac insufficiency, hypertension, type 2 diabetes mellitus) and implanted with a cardiac pacemaker, was treated with safe (means that the patient has not developed heart disease because of the pacemaker problem) and effective (tumor can be effectively controlled under the condition that the pacemaker does not malfunction) radiotherapy. At present, the patient has successfully completed radiation therapy for breast cancer with no recurrence or metastasis. To the best of our knowledge, the present report is the first to document this application, demonstrating the treatment of a patient with breast cancer and cardiac pacemaker implantation, which is worthy of further study and continuous improvement in clinical practice.